A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination

NCT ID: NCT01963338

Last Updated: 2016-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to assess the acceptability and usability of a newly developed intradermal device in healthy adults

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Vaccination Adverse Event

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intradermal group

These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).

Group Type EXPERIMENTAL

Intradermal injection in the forearm (0,1cc NaCl 0,9%)

Intervention Type DEVICE

This injection is conducted by the newly developed device.

Intradermal injection in the upper arm (0,1cc NaCl 0,9%)

Intervention Type DEVICE

This injection is conducted by the newly developed device in the upper arm (deltoid region).

Intramuscular group

These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.

Group Type EXPERIMENTAL

Intradermal injection in the forearm (0,1cc NaCl 0,9%)

Intervention Type DEVICE

This injection is conducted by the newly developed device.

Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)

Intervention Type DRUG

This injection is conducted by needle and syringe in the upper arm (deltoid region).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intradermal injection in the forearm (0,1cc NaCl 0,9%)

This injection is conducted by the newly developed device.

Intervention Type DEVICE

Intradermal injection in the upper arm (0,1cc NaCl 0,9%)

This injection is conducted by the newly developed device in the upper arm (deltoid region).

Intervention Type DEVICE

Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)

This injection is conducted by needle and syringe in the upper arm (deltoid region).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy adults

Exclusion Criteria

* people who have regular experience with needle injections, e.g. diabetic patients
* pregnant women
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pierre Van Damme

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pierre Van Damme

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre Van Damme, Prof.

Role: STUDY_DIRECTOR

Universiteit Antwerpen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Antwerp

Wilrijk, Antwerp, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

Van Mulder TJ, Verwulgen S, Beyers KC, Scheelen L, Elseviers MM, Van Damme P, Vankerckhoven V. Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects. Hum Vaccin Immunother. 2014;10(12):3746-53. doi: 10.4161/21645515.2014.979655.

Reference Type DERIVED
PMID: 25531808 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

cev2012-vaxid

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers
NCT06975319 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Anthrax AV7909 Liquid vs Lyophilized
NCT04660201 COMPLETED PHASE1